Comparative Pharmacology
Head-to-head clinical analysis: EMCYT versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMCYT versus URACIL MUSTARD.
EMCYT vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estramustine is a combination of estradiol and nitrogen mustard. The estradiol moiety targets the drug to cells expressing estrogen receptors, while the nitrogen mustard alkylates DNA, inhibiting cell division primarily in prostate cancer cells.
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
Estramustine phosphate sodium: 14 mg/kg/day orally in 3-4 divided doses, typically 140 mg four times daily. Administer on an empty stomach (1 hour before or 2 hours after meals).
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Deslanoside
"Uracil mustard may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateUracil mustard + Acetyldigitoxin
"Uracil mustard may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of estramustine phosphate: ~20 hours; estromustine: ~14 hours; clinical context: supports daily dosing with accumulation over 5-7 days
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Renal: primarily as estramustine phosphate, estromustine, and estradiol; <1% as unchanged drug; fecal: ~15%
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category C
Category C
Alkylating Agent
Alkylating Agent